Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited standalone financial results for FY ended March 31, 2025, with the statutory auditor issuing an unmodified opinion. Revenue from operations grew about 31% year-on-year to ₹899.86 lakhs (vs ₹687.85 lakhs in FY24), while total revenue rose to ₹955.40 lakhs. However, the company swung to a loss with a Profit After Tax of ₹-32.72 lakhs compared to a profit of ₹60.72 lakhs in the previous year, as total expenses surged roughly 48% to ₹988.04 lakhs driven by higher employee costs, depreciation (₹101.27 lakhs vs ₹37.91 lakhs), and other expenses. EPS turned negative at ₹-0.48. Operating cash flow improved to ₹225.49 lakhs, but cash reserves dipped to ₹36.92 lakhs after heavy capital expenditure of ₹692.47 lakhs on property, plant and equipment. The board also appointed a new internal auditor for FY26 and a secretarial auditor for a five-year term through FY30.
Despite strong top-line growth, sharp expense increases pushed the hospital into a loss for the year, which is a negative signal for shareholders. Heavy capital spending signals expansion plans, but the profitability reversal and depleted cash position warrant close monitoring of future quarterly performance.